Global Drug Eluting Implants Market - Forecasts from 2018 to 2023

February 2018 | 81 pages | ID: G51D717A641EN
Knowledge Sourcing Intelligence LLP

Abstracts

The global drug eluting implants market is expected to reach US$8.120 billion by the end of 2023, increasing from US$5.594 billion in 2017, growing at a CAGR of 6.41% during the forecast period. Drug Eluting implants carry drugs for the on-site drug delivery which helps in improving the effectiveness of the treatment, minimize side-effects or damage to the healthy tissues. These implants proved to be a game changer technology in the field of healthcare with the arrival of Drug Eluting Stents (DES). Growing adoption of these devices and increasing expenditure in the field of research and development will be the major factors driving the demand for these implants. North America and Europe held a significant share in 2017 and the Asia Pacific region is projected grow at an impressive rate over the forecast period.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the pressure sensors value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Boston Scientific, ProMed Pharma, Elixir Medical Corporation, iVascular, and Abbott Laboratories among others.

Segmentation

The Global Drug Eluting Implants market has been analyzed through following segments:

By Type

• Biodegradable Drug Eluting Implants
• Non-Biodegradable Drug Eluting Implants

By Application

• Cardiology
• Oncology
• Diabetes Treatment
• Pain Treatment
• Others

By Geography

• North America
• South America
• Europe
• Middle East and Africa
• Asia Pacific

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL DRUG ELUTING IMPLANTS MARKET BY TYPE

5.1. Biodegradable Drug Eluting Implants
5.2. Non-Biodegradable Drug Eluting Implants

6. GLOBAL DRUG ELUTING IMPLANTS MARKET BY APPLICATION

6.1. Cardiology
6.2. Oncology
6.3. Diabetes Treatment
6.4. Pain Treatment
6.5. Others

7. GLOBAL DRUG ELUTING IMPLANTS MARKET BY GEOGRAPHY

7.1. North America
7.2. South America
7.3. Europe
7.4. Middle East and Africa
7.5. Asia Pacific

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Investment Analysis
8.3. Recent Deals
8.4. Strategies of Key Players

9. COMPANY PROFILES

9.1. iVascular
  9.1.1. Company Overview
  9.1.2. Financials
  9.1.3. Products and Services
  9.1.4. Recent Developments
9.2. ProMed Pharma
  9.2.1. Company Overview
  9.2.2. Financials
  9.2.3. Products and Services
  9.2.4. Recent Developments
9.3. Johnson & Johnson
  9.3.1. Company Overview
  9.3.2. Financials
  9.3.3. Products and Services
  9.3.4. Recent Developments
9.4. Boston Scientific
  9.4.1. Company Overview
  9.4.2. Financials
  9.4.3. Products and Services
  9.4.4. Recent Developments
9.5. Merck
  9.5.1. Company Overview
  9.5.2. Financials
  9.5.3. Products and Services
  9.5.4. Recent Developments
9.6. Medtronic
  9.6.1. Company Overview
  9.6.2. Financials
  9.6.3. Products and Services
  9.6.4. Recent Developments
9.7. Biosensors International Group
  9.7.1. Company Overview
  9.7.2. Financials
  9.7.3. Products and Services
  9.7.4. Recent Developments
9.8. Abbott Laboratories
  9.8.1. Company Overview
  9.8.2. Financials
  9.8.3. Products and Services
  9.8.4. Recent Developments
9.9. Elixir Medical Corporation
  9.9.1. Company Overview
  9.9.2. Financials
  9.9.3. Products and Services
  9.9.4. Recent Developments
9.10. Siemens Healthcare
  9.10.1. Company Overview
  9.10.2. Financials
  9.10.3. Products and Services
  9.10.4. Recent Developments